Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

BACKGROUND: Although anti-VEGF therapy of exudative AMD with bevacizumab and ranibizumab proved efficacious in the majority of patients, CNV activity does not respond to continued treatment after repeated injections in a considerable amount of patients. These are referred to as nonresponders. A chan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ehlken, C, Jungmann, S, Böhringer, D, Agostini, H T, Junker, B, Pielen, A
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017123/
https://ncbi.nlm.nih.gov/pubmed/24722504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/eye.2014.64
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars